Reply to “PCSK9: Entering a new era of cardiovascular risk prediction”

We would thank Dr. Schindler and Leucker for their valuable comments [1] on our recent publication in International Journal of Cardiology [2]. We have particularly appreciated their focus on the main innovative aspect of our research study: the potential pro-atherosclerotic activity of proprotein convertase subtilisin/kexin type 9 (PCSK9), which are independent of low density lipoprotein (LDL) levels.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research